All-cause and cause-specific mortality in microscopic colitis: a Danish nationwide matched cohort study.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
10
03
2020
revised:
09
04
2020
accepted:
18
05
2020
pubmed:
26
6
2020
medline:
11
11
2020
entrez:
26
6
2020
Statut:
ppublish
Résumé
The long-term natural history of microscopic colitis remains uncertain. To describe the mortality in a large unselected cohort of patients with microscopic colitis. All Danish patients above 18 years with an incident diagnosis of microscopic colitis from 2001 to 2018 were identified from nationwide registries and compared to age- and sex-matched controls (variable 1:10 ratio). Patients were categorised according to subtypes: lymphocytic colitis and collagenous colitis. The relative risk of death by any cause was analysed with Cox regression models estimating both crude and comorbidity-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). Cause-specific death was evaluated with cumulative incidence functions. An E-value was calculated to address the impact of unmeasured confounding. The final cohort consisted of 14 024 patients with microscopic colitis. The mean follow-up was 5.8 (standard deviation SD, 2.9) years and the mean age at diagnosis was 61.1 (SD 13.9) years, 70% were women and 41% were diagnosed with lymphocytic colitis. The main results showed a 25% increased risk of all-cause death in patients with microscopic colitis; however, the relative risk was attenuated to 9% when adjusting for comorbidities (95% CI, 1.05-1.14). The E-value indicates that unmeasured confounding could explain the residual observed increased all-cause mortality. Mortality was significantly increased in patients with both lymphocytic colitis (HR 1.15; 95% CI, 1.08-1.23) and collagenous colitis (HR 1.06; 95% CI, 1.01-1.12) in fully adjusted analyses. The absolute difference in death between patients with microscopic colitis and matches was 0.9% at 1 year, 2.8% at 5 years, 5.0% at 10 years and 3.0% at 15 years. Cumulative incidence functions showed that patients with microscopic colitis were more likely to die due to smoking-related diseases including ischemic heart and lung diseases, but had a significant decreased risk of death due to colorectal cancers (P < 0.0001). In an unselected large nationwide cohort of patients with microscopic colitis, the risk of death was significantly increased compared to the background population. However, the increased mortality seemed to be associated to a high burden of comorbidities and unmeasured life-style factors including smoking and not microscopic colitis per se.
Sections du résumé
BACKGROUND
The long-term natural history of microscopic colitis remains uncertain.
AIM
To describe the mortality in a large unselected cohort of patients with microscopic colitis.
METHODS
All Danish patients above 18 years with an incident diagnosis of microscopic colitis from 2001 to 2018 were identified from nationwide registries and compared to age- and sex-matched controls (variable 1:10 ratio). Patients were categorised according to subtypes: lymphocytic colitis and collagenous colitis. The relative risk of death by any cause was analysed with Cox regression models estimating both crude and comorbidity-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). Cause-specific death was evaluated with cumulative incidence functions. An E-value was calculated to address the impact of unmeasured confounding.
RESULTS
The final cohort consisted of 14 024 patients with microscopic colitis. The mean follow-up was 5.8 (standard deviation SD, 2.9) years and the mean age at diagnosis was 61.1 (SD 13.9) years, 70% were women and 41% were diagnosed with lymphocytic colitis. The main results showed a 25% increased risk of all-cause death in patients with microscopic colitis; however, the relative risk was attenuated to 9% when adjusting for comorbidities (95% CI, 1.05-1.14). The E-value indicates that unmeasured confounding could explain the residual observed increased all-cause mortality. Mortality was significantly increased in patients with both lymphocytic colitis (HR 1.15; 95% CI, 1.08-1.23) and collagenous colitis (HR 1.06; 95% CI, 1.01-1.12) in fully adjusted analyses. The absolute difference in death between patients with microscopic colitis and matches was 0.9% at 1 year, 2.8% at 5 years, 5.0% at 10 years and 3.0% at 15 years. Cumulative incidence functions showed that patients with microscopic colitis were more likely to die due to smoking-related diseases including ischemic heart and lung diseases, but had a significant decreased risk of death due to colorectal cancers (P < 0.0001).
CONCLUSION
In an unselected large nationwide cohort of patients with microscopic colitis, the risk of death was significantly increased compared to the background population. However, the increased mortality seemed to be associated to a high burden of comorbidities and unmeasured life-style factors including smoking and not microscopic colitis per se.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-328Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Pisani LF, Tontini GE, Marinoni B, et al. Biomarkers and microscopic colitis: an unmet need in clinical practice. Front Med. 2017;4:54.
Jaruvongvanich V, Poonsombudlert K, Ungprasert P. Smoking and risk of microscopic colitis: a systematic review and meta-Analysis. Inflamm Bowel Dis. 2019;25:672-678.
Lucendo AJ. Drug exposure and the risk of microscopic colitis: a critical update. Drugs R D. 2017;17:79-89.
Storr MA. Microscopic colitis: epidemiology, pathophysiology, diagnosis and current management-an update 2013. ISRN Gastroenterol. 2013;2013:352718.
Miehlke S, Madisch A, Karimi D, et al. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology. 2009;136:2092-2100.
Miehlke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology. 2002;123:978-984.
Bohr J, Wickbom A, Hegedus A, Nyhlin N, Hörnquist EH, Tysk C. Diagnosis and management of microscopic colitis: current perspectives. Clin Exp Gastroenterol. 2014;7:273-284.
Loreau J, Duricova D, Gower-Rousseau C, et al. Long-term natural history of microscopic colitis. Clin Transl Gastroenterol. 2019;10:e00071.
Nyhlin N, Wickbom A, Montgomery SM, Tysk C, Bohr J. Long-term prognosis of clinical symptoms and health-related quality of life in microscopic colitis: a case-control study. Aliment Pharmacol Ther. 2014;39:963-972.
Fernández-Bañares F, Zabana Y, Aceituno M, Ruiz L, Salas A, Esteve M. Prevalence and natural history of microscopic colitis: a population-based study with long-term clinical follow-up in Terrassa, Spain. J Crohn's Colitis. 2016;10:805-811.
Chan JL, Tersmette AC, Offerhaus GJA, Gruber SB, Bayless TM, Giardiello FM. Cancer risk in collagenous colitis. Inflamm Bowel Dis. 1999;5:40-43.
Khalili H, Roelstraete B, Burke KE, et al. Mortality in microscopic colitis - results from a nationwide cohort study. Gastroenterology. 2019;156:S101.
Pedersen CB, Gøtzsche H, Møller JØ, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53:441-449.
Bjerregaard B, Larsen OB. The Danish pathology register. Scand J Public Health. 2011;37:72-74.
Andersen TF, Madsen M, Jørgensen J, Mellemkjaer L, Olsen JH. The Danish National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263-268.
Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39:26-29.
Charlson ME, Pompei P, Ales KL, MacKenzie R. Charlson comorbidity index. J Chronic Dis. 1987;40:373-383.
Van Der Weele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-Value. Ann Intern Med. 2017;27:571-574.
Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc. 2010;58:783-787.
Zhang MJ, Zhang X, Scheike TH. Modeling cumulative incidence function for competing risks data. Expert Rev Clin Pharmacol. 2008;1:391-400.
Rasmussen MA, Munck LK. Systematic review: are lymphocytic colitis and collagenous colitis two subtypes of the same disease - microscopic colitis? Aliment Pharmacol Ther. 2012;36:79-90.
Fiehn AMK, Bjørnbak C, Warnecke M, Engel PJH, Munck LK. Observer variability in the histopathologic diagnosis of microscopic colitis and subgroups. Hum Pathol. 2013;44:2461-2466.
Davidson S, Sjöberg K, Engel PJH, et al. Microscopic colitis in Denmark and Sweden: incidence, putative risk factors, histological assessment and endoscopic activity. Scand J Gastroenterol. 2018;53:818-824.
Vigren L, Sjöberg K, Benoni C, et al. Is smoking a risk factor for collagenous colitis? Scand J Gastroenterol. 2011;46:1334-1339.
Larsson JK, Dabos KJ, Höglund P, et al. Cancer risk in collagenous colitis. J Clin Med. 2019;8:1942.
Yen EF, Pokhrel B, Bianchi LK, et al. Decreased colorectal cancer and adenoma risk in patients with microscopic colitis. Dig Dis Sci. 2012;57:161-169.
Tontini GE, Pastorelli L, Spina L, et al. Microscopic colitis and colorectal neoplastic lesion rate in chronic nonbloody diarrhea: a prospective, multicenter study. Inflamm Bowel Dis. 2014;20:882-891.
Pelizza L, Melegari M. Clozapine-induced microscopic colitis: a case report and review of the literature. J Clin Psychopharmacol. 2007;27:571-574.
Bonderup OK, Fenger-Grøn M, Wigh T, Pedersen L, Nielsen GL. Drug exposure and risk of microscopic colitis: a nationwide Danish case-control study with 5751 cases. Inflamm Bowel Dis. 2014;20:1702-1707.
Lawrence D, Kisely S, Pais J. The epidemiology of excess mortality in people with mental illness. Can J Psychiatry. 2010;55:752-759.
Bonderup OK, Nielsen GL, Dall M, Pottegård A, Hallas J. Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study. Aliment Pharmacol Ther. 2018;48:618-625.
Verhaegh BPM, de Vries F, Masclee AAM, et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther. 2016;43:1004-1013.
Masclee GMC, Coloma PM, Kuipers EJ, Sturkenboom MCJM. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol. 2015;110:749-759.